Journal Logo



Faderl, S.1; Schiller, G. J.2; Ryan, R. J.1; Chiarella, M.1; Cortes, J. E.3

doi: 10.1097/01.HS9.0000559384.63171.f2
Poster Session I: Acute myeloid leukemia - Clinical

1Jazz Pharmaceuticals, Palo Alto, CA

2David Geffen School of Medicine of UCLA, Los Angeles, CA

3The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Back to Top | Article Outline


CPX-351 (Vyxeos®; daunorubicin and cytarabine powder for concentrate for solution for infusion), a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved by the EMA and US FDA for the treatment of adults with newly diagnosed, therapy-related AML or AML with myelodysplasia-related changes. In a randomized phase 3 study, induction followed by consolidation with CPX-351 significantly improved median overall survival (OS) versus conventional 7+3 cytarabine/daunorubicin chemotherapy (9.56 vs 5.95 months; HR = 0.69 [95% CI: 0.52-0.90; 1-sided P = 0.003) and had a safety profile comparable to 7+3 in adults aged 60-75 years with newly diagnosed, high-risk/secondary AML (Lancet, et al. J Clin Oncol 2018). CPX-351 was also associated with significantly higher rates versus 7+3 of complete remission (CR) or CR with incomplete platelet or neutrophil recovery (CR+CRi; 73/153 [48%] vs 52/156 [33%]; OR = 1.77 [95% CI: 1.11-2.81]; 2-sided P = 0.016) and CR (57/153 [37%] vs 40/156 [26%]; OR = 1.69 [95% CI: 1.03-2.78]; 2-sided P = 0.040).

Back to Top | Article Outline


This exploratory analysis of the phase 3 study evaluated outcomes in the subgroup of patients (pts) who achieved CR+CRi following induction with CPX-351 versus 7+3.

Back to Top | Article Outline


A total of 309 pts were randomized 1:1 to receive up to 2 induction cycles of CPX-351 (100 units/m2 [daunorubicin 44 mg/m2 + cytarabine 100 mg/m2] on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (cytarabine 100 mg/m2/day continuously for 7 days [2nd induction: 5 days] + daunorubicin 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Pts achieving CR+CRi could receive up to 2 consolidation cycles with CPX-351 (65 units/m2 [daunorubicin 29 mg/m2 + cytarabine 65 mg/m2] on Days 1 and 3) or 5+2 (as for 2nd induction). For this analysis, outcomes were evaluated in the subgroup of pts who achieved CR+CRi following induction.

Back to Top | Article Outline


Baseline characteristics of pts who achieved CR+CRi were generally balanced between arms. Median OS was longer with CPX-351 versus 7+3 in pts who achieved CR+CRi (25.43 vs 10.41 months; HR = 0.49 [95% CI: 0.31-0.77]) or CR (25.43 vs 10.97 months; HR = 0.49 [95% CI: 0.29-0.83]; Figure 1). Of pts who achieved CR+CRi, 40/73 (55%) in the CPX-351 arm and 24/52 (46%) in the 7+3 arm underwent transplantation (OR = 0.71 [95% CI: 0.35-1.44]; median OS landmarked from the date of transplant was not reached versus 11.65 months, respectively (HR = 0.42 [95% CI: 0.20-0.86]; Figure 2). Serious treatment-emergent adverse events in ≥5% of pts who achieved CR+CRi were febrile neutropenia (CPX-351: 15%; 7+3: 12%), acute respiratory failure (7%; 2%), ejection fraction decreased (5%; 4%), sepsis (5%; 4%), pneumonia (3%; 6%), and pulmonary edema (1%; 6%). Four pts with CR+CRi died during the treatment phase (sepsis [CPX-351]; atrial fibrillation [7+3]; disease progression [7+3]; intracranial hemorrhage [7+3]); no patient experienced early mortality (within 60 days) in either arm. Median time for recovery to neutrophils ≥1,000/μL and platelets ≥100,000/μL, respectively, in pts who achieved CR+CRi was longer with CPX-351 (37 and 42 days) versus 7+3 (29 and 32 days).



Back to Top | Article Outline


Among pts who achieved CR+CRi in this study, those who received CPX-351 had longer median OS, a higher rate of transplantation, and longer median OS landmarked from the date of transplant versus 7+3, suggesting potentially deeper responses may be achieved with CPX-351. The safety profile of CPX-351 in pts who achieved CR+CRi was consistent with the known profile of 7+3, as well as the overall study population.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.